Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Documenti analoghi

• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)
• Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy
  di: Frank M. Gao, et al.
  Pubblicazione: (2025)
• Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
  di: João Sérgio Neves, et al.
  Pubblicazione: (2025)
• One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
  di: Louise A. Donnelly, et al.
  Pubblicazione: (2025)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  di: Nicklas S. Klepser, et al.
  Pubblicazione: (2025)